BioNTech will announce Q1 2026 financial results on May 5, 2026, with a conference call for discussion.
Quiver AI Summary
BioNTech SE will release its financial results for the first quarter of 2026 on May 5, 2026, and will host a conference call and webcast at 8:00 a.m. ET to discuss these results and provide a corporate update. Participants can register for the call to receive dial-in information, and the presentation will also be accessible on the company's website. BioNTech is a biopharmaceutical company focused on pioneering immunotherapy treatments for cancer and other diseases, utilizing advanced modalities like mRNA technologies and collaborating with multiple major pharmaceutical companies. The company emphasizes its diverse oncology pipeline and capability in developing mRNA vaccine candidates for various infectious diseases. For further details, interested parties can visit BioNTech's website.
Potential Positives
- BioNTech will announce its financial results for Q1 2026, demonstrating transparency and accountability to investors.
- The scheduled conference call and webcast provide an opportunity for direct engagement with investors, financial analysts, and the public.
- BioNTech's extensive pipeline of oncology product candidates and mRNA vaccine candidates underscores its innovative approach and commitment to addressing serious diseases.
- The company has established relationships with major pharmaceutical collaborators, indicating strong partnerships and potential for successful development and commercialization of therapies.
Potential Negatives
- None
FAQ
When will BioNTech announce its Q1 2026 financial results?
BioNTech will announce its financial results for Q1 2026 on May 5, 2026.
How can I access the BioNTech conference call?
You can access the conference call by registering via the link provided in the announcement.
What time is the BioNTech conference call on May 5, 2026?
The conference call will be held at 8:00 a.m. ET (2:00 p.m. CET).
Where can I find the replay of the BioNTech webcast?
The webcast replay will be available on BioNTech’s website for 30 days after the call.
What services does BioNTech provide?
BioNTech specializes in next-generation immunotherapies for cancer and infectious diseases, including mRNA vaccines.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNTX Hedge Fund Activity
We have seen 134 institutional investors add shares of $BNTX stock to their portfolio, and 112 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAILLIE GIFFORD & CO removed 6,634,492 shares (-84.2%) from their portfolio in Q4 2025, for an estimated $631,603,638
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,746,944 shares (-36.1%) from their portfolio in Q4 2025, for an estimated $166,309,068
- PFIZER INC removed 1,658,361 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $157,875,967
- JANE STREET GROUP, LLC added 1,164,203 shares (+590.9%) to their portfolio in Q4 2025, for an estimated $110,832,125
- D. E. SHAW & CO., INC. added 488,552 shares (+inf%) to their portfolio in Q4 2025, for an estimated $46,510,150
- FMR LLC added 480,114 shares (+8.8%) to their portfolio in Q4 2025, for an estimated $45,706,852
- BNP PARIBAS FINANCIAL MARKETS added 474,796 shares (+43.0%) to their portfolio in Q4 2025, for an estimated $45,200,579
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BNTX Analyst Ratings
Wall Street analysts have issued reports on $BNTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for $BNTX, check out Quiver Quantitative's $BNTX forecast page.
$BNTX Price Targets
Multiple analysts have issued price targets for $BNTX recently. We have seen 9 analysts offer price targets for $BNTX in the last 6 months, with a median target of $130.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $126.0 on 04/10/2026
- Robert Burns from HC Wainwright & Co. set a target price of $130.0 on 03/31/2026
- Etzer Darout from BMO Capital set a target price of $128.0 on 03/11/2026
- Geoff Meacham from Citigroup set a target price of $130.0 on 03/11/2026
- Yaron Werber from TD Cowen set a target price of $94.0 on 03/11/2026
- John Newman from Canaccord Genuity set a target price of $171.0 on 03/11/2026
- Akash Tewari from Jefferies set a target price of $138.0 on 03/10/2026
Full Release
MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE)
--
BioNTech SE
(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this
link
. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this
link
.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at
www.BioNTech.com
. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com .
CONTACTS
Investor Relations
Douglas Maffei, PhD
[email protected]
Media Relations
Jasmina Alatovic
[email protected]
